At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 35 enrolled
Drug / intervention
AcrySof ReSTOR Aspheric IOL model SN6AD1device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1
In Brief
A Phase 4 clinical trial evaluating AcrySof ReSTOR Aspheric IOL model SN6AD1 for Cataract. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The objective of this study is to prospectively evaluate the visual parameters in a series of patients after phacoemulsification cataract surgery in a series of patients bilaterally implanted with the AcrySof® ReSTOR® Aspheric +3.0 Intraocular Lens (IOL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartOct 2008
Primary CompletionSep 2010
TodayJul 2026
First PostedJul 8, 2008
Enrollment StartOct 1, 2008
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.0 years ago
Interventions
AcrySof ReSTOR Aspheric IOL model SN6AD1device
Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL) following cataract removal.